Literature DB >> 20567014

Do we have to change the way targeted drugs are developed?

Alberto Ocana, Eitan Amir, Bostjan Seruga, Atanasio Pandiella.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20567014     DOI： 10.1200/JCO.2010.28.9918

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

Review 2.  Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.

Authors:  Sadegh Rajabi; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

3.  Personalized oncology through integrative high-throughput sequencing: a pilot study.

Authors:  Sameek Roychowdhury; Matthew K Iyer; Dan R Robinson; Robert J Lonigro; Yi-Mi Wu; Xuhong Cao; Shanker Kalyana-Sundaram; Lee Sam; O Alejandro Balbin; Michael J Quist; Terrence Barrette; Jessica Everett; Javed Siddiqui; Lakshmi P Kunju; Nora Navone; John C Araujo; Patricia Troncoso; Christopher J Logothetis; Jeffrey W Innis; David C Smith; Christopher D Lao; Scott Y Kim; J Scott Roberts; Stephen B Gruber; Kenneth J Pienta; Moshe Talpaz; Arul M Chinnaiyan
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

4.  Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies.

Authors:  Karen Gómez; Jeena Varghese; Camilo Jiménez
Journal:  J Thyroid Res       Date:  2011-05-16

5.  Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Authors:  Serena Giunti; Alessandro Antonelli; Andrea Amorosi; Libero Santarpia
Journal:  Int J Endocrinol       Date:  2013-02-21       Impact factor: 3.257
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.